



CAPPELLO

GROUP INC.

MERCHANT BANKERS

FOR IMMEDIATE RELEASE

Cappello Group, Inc. Forms New Life Sciences and Biotechnology Group, Paul A. Hopper appointed as Head

SANTA MONICA, California (December 14th, 2009) - Cappello Group, Inc. has recently formed a new Life Sciences and Biotechnology Group that will focus on emerging biotechnology, specialty pharma, and healthcare services. The group will utilize the diverse skills of its senior principal to provide a wide range of services that include M & A, partnerships and licensing, capital raisings and strategic advice.

Cappello has appointed Paul A. Hopper to lead its effort in this new venture. Mr. Hopper has over 20 years experience in the healthcare sector as both an entrepreneur and business operator and has served as either CEO, Director or Chairman of a dozen biotechnology and healthcare companies in the US, Asia and Australia. Currently he is a Director of pSivida Corp, which is in Phase 3 trials for an ophthalmic drug delivery device, a Director of Fibrocell Sciences which following successful Phase 3 trials has filed a BLA with the FDA, a Director of Somnomed Ltd which internationally manufactures and markets an oral device for sleep disorders and is the Chairman of Viralytics Ltd which is developing an oncolytic cancer vaccine. He is the founder of a private US biotech, which will enter Phase 3 clinical trials in 2010 for a melanoma cancer vaccine. He has extensive capital markets networks in the biotechnology and healthcare sectors both in the US, and internationally.

Cappello Group, Inc., is a boutique investment bank focusing on buy/sell side M&A, strategic advisory, financial restructuring and private placements of equity and debt for both private and public companies. Cappello's principals have significant cross-border transactional experience in excess of \$100 billion for companies in over 50 countries in North America, Latin America, South America, Europe, Australia, Asia, Africa and the Middle East.